Log in to search using one of your social media accounts:

 

New glaucoma drugs yield large, lasting reductions in intraocular pressure
(Mary Ann Liebert, Inc./Genetic Engineering News) Two novel ocular hypotensive agents that have just been approved for use in humans -- netarsudil and latanoprostene bunod (LBN) -- greatly reduce intraocular pressure, with lasting results in various animal models of glaucoma and in humans. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - February 21, 2018 Category: International Medicine & Public Health Source Type: news

Factors associated with developing a fear of falling in subjects with primary open-angle glaucoma - Adachi S, Yuki K, Awano-Tanabe S, Ono T, Shiba D, Murata H, Asaoka R, Tsubota K.
BACKGROUND: To investigate the relationship between clinical risk factors, including visual field (VF) defects and visual acuity, and a fear of falling, among patients with primary open-angle glaucoma (POAG). METHODS: All participants answered the ... (Source: SafetyLit)
Source: SafetyLit - February 19, 2018 Category: International Medicine & Public Health Tags: Age: Elder Adults Source Type: news

Guard Against Glaucoma: Ophthalmology Times
(MedPage Today) -- Also, understanding glaucoma on a cellular level (Source: MedPage Today Primary Care)
Source: MedPage Today Primary Care - February 14, 2018 Category: Primary Care Source Type: news

Trabeculectomy After Failed Glaucoma Drainage Device Surgery Trabeculectomy After Failed Glaucoma Drainage Device Surgery
Is trabeculectomy a good option for patients with increased IOP after failure of glaucoma drainage device surgery?Medscape Ophthalmology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - February 13, 2018 Category: Consumer Health News Tags: Ophthalmology Viewpoint Source Type: news

Neutron study of glaucoma drugs offers clues about enzyme targets for aggressive cancers
(DOE/Oak Ridge National Laboratory) A team of researchers from ORNL's Energy and Transportation Science Division is using neutron imaging to study particulate filters that collect harmful emissions in vehicles. A better understanding of how heat treatments and oxidation methods can remove layers of soot and ash from these filters could lead to improved fuel-efficiency. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - February 12, 2018 Category: International Medicine & Public Health Source Type: news

Glaukos touts IOP, medication use reductions in iStent trial
Glaukos (NYSE:GKOS) today released results from a study of its iStent trabecular micro-bypass stent exploring its use during cataract surgery in patients with severe open-angle glaucoma, touting significant reductions in intraocular pressure and medication use. The San Clemente, Calif.-based company’s iStent micro-bypass stents are made from non-ferromagnetic titanium and coated in heparin, is designed to be implanted into multiple trabecular meshwork through a single corneal entry point to reduce IOP. Results were published in the January issue of the Journal of Glaucoma. “Although the iStent&nb...
Source: Mass Device - February 8, 2018 Category: Medical Devices Authors: Fink Densford Tags: Clinical Trials Optical/Ophthalmic Glaukos Source Type: news

Could hiring 100 sales reps catapult revenue over $100M next year at Durham's Aerie Pharmaceuticals?
As Duke University spinout Aerie Pharmaceuticals plans to launch its first U.S. Food and Drug Administration-approved glaucoma product Rhopressa in the second quarter, its hiring of 100 sales representatives early this year could put sales soaring in 2019. (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - February 8, 2018 Category: Biotechnology Authors: Jennifer Henderson Source Type: news

You Asked: Can Hanging Upside Down Relieve Back Pain?
If you’ve ever seen a TV commercial for inversion tables—those tilting contraptions that allow you to hang upside down by your ankles—and you suffer from back pain, you’ve probably been tempted to buy one. The ads claim that by dangling upside-down, bat-like, you’ll create separation between the vertebrae of your spine and neck. That separation supposedly reduces pressure on the nerves running between and around these vertebrae. You’ll relax tense muscles, and increase the flow of “nutrients” to the disks of your spine—all of which should help relieve back pain and prom...
Source: TIME: Health - February 7, 2018 Category: Consumer Health News Authors: Markham Heid Tags: Uncategorized Back Pain benefits of hanging upside down Exercise/Fitness healthytime inversion table inversion table therapy is hanging upside down good for you remedies for back pain what does an inversion table do yoga yoga headsta Source Type: news

The Growing Glaucoma Drug Landscape: Ophthalmology Times
(MedPage Today) -- Also, should we test new policies like we test new drugs? (Source: MedPage Today Primary Care)
Source: MedPage Today Primary Care - February 7, 2018 Category: Primary Care Source Type: news

Second Sight touts 1st-in-human Orion cortical implant
Second Sight Medical (NSDQ:EYES) today announced the first trial implantation of its Orion cortical visual prosthesis system and updated on implantations of its Argus device and enrollment in an upcoming study. The first implantation procedure was performed late last month by Dr. Nader Pouratian at the Ronald Reagan UCLA Medical Center, the Sylmar, Calif.-based company said, as part of an FDA-cleared feasibility trial it won approval to launch last November. The Orion cortical visual prosthesis system is designed to convert images captured by a miniature video camera, mounted on a patient’s glasses, into a ...
Source: Mass Device - February 5, 2018 Category: Medical Devices Authors: Fink Densford Tags: Clinical Trials Optical/Ophthalmic Second Sight Source Type: news

Should I Worry About This Telangiectasia?
Discussion Vascular stains are common problems that parents seek guidance about as they are often particularly worried that there may be an underlying problem or that it may be a long-term cosmetic problem. Fortunately many resolve or become less prominent or have treatment available. The term vascular stains includes all vascular malformations but commonly refers more directly to capillary malformations which are quite common. Some common vascular stains include: Nevus simplex Names: Angel’s kiss (glabella or forehead), salmon patch, stork bite (nape of neck), nevus roseus, fading macular stain Epidemiology: Very ...
Source: PediatricEducation.org - January 29, 2018 Category: Pediatrics Authors: pediatriceducationmin Tags: Uncategorized Source Type: news

Innovation Lab eyes local professor as first incubator tenant
The University of Tennessee Health Science Center (UTHSC) has selected a local ophthalmology professor as the first user of its new Innovation Lab. Monica M. Jablonski, who works in UTHSC's College of Medicine, is developing a topical mixture that works better than standard eye drops and is working to improve treatments for conditions such as glaucoma and age-related macular degeneration. Jablonski and her company, OculoTherapy LLC, will ha ve access to the 420-square-foot space within the Memphis… (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - January 24, 2018 Category: Pharmaceuticals Authors: Elle Perry Source Type: news

Innovation Lab eyes local professor as first incubator tenant
The University of Tennessee Health Science Center (UTHSC) has selected a local ophthalmology professor as the first user of its new Innovation Lab. Monica M. Jablonski, who works in UTHSC's College of Medicine, is developing a topical mixture that works better than standard eye drops and is working to improve treatments for conditions such as glaucoma and age-related macular degeneration. Jablonski and her company, OculoTherapy LLC, will ha ve access to the 420-square-foot space within the Memphis… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - January 24, 2018 Category: Biotechnology Authors: Elle Perry Source Type: news

Mayo Clinic-Backed Startup Will Use AI to Target Unmet Medical Needs
The objective is to figure out how to maximize the cohort that has an unmet need. If the subset is a reasonable subset, it's still interesting from a commercial standpoint." Hear Mark Wehde, of Mayo Clinic's Division of Engineering, discuss new product iteration at the MD&M West Conference on February 7, 2018. Use promo code "MDDI" for 20% off registration. The Qrativ Approach Qrativ formed after Dr. Andrew Badley, Mayo Clinic's director of the Office of Translation, accomplished in two months what his lab had been unable to accomplish in the prior two years by using nference's nferX synthesis platform. ...
Source: MDDI - January 23, 2018 Category: Medical Devices Authors: Heather R. Johnson Tags: Medical Device Business Source Type: news

Improving Glaucoma Care: Ophthalmology Times
(MedPage Today) -- Also, telemedicine for boosting ROP screening (Source: MedPage Today Primary Care)
Source: MedPage Today Primary Care - January 16, 2018 Category: Primary Care Source Type: news

Study advances gene therapy for glaucoma
(University of Wisconsin-Madison) In a study published today in the scientific journal Investigative Ophthalmology and Visual Science, Kaufman and Curtis Brandt, a fellow professor of ophthalmology and visual sciences at UW-Madison, showed an improved tactic for delivering new genes into the eye's fluid drain, called the trabecular meshwork. It could lead to a treatment for glaucoma. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - January 16, 2018 Category: International Medicine & Public Health Source Type: news

Combining Cataract Surgery, Baerveldt-tube Implant Sometimes Useful for Glaucoma Combining Cataract Surgery, Baerveldt-tube Implant Sometimes Useful for Glaucoma
Cataract surgery and implantation of a Baerveldt tube (BT) for glaucoma should be done separately in most cases, but may be combined in some, research from Switzerland suggests.Reuters Health Information (Source: Medscape General Surgery Headlines)
Source: Medscape General Surgery Headlines - January 11, 2018 Category: Surgery Tags: Ophthalmology News Source Type: news

Glaukos touts Ph2 glaucoma trial for drug-eluting implant
Glaukos (NYSE:GKOS) touted data today from a Phase II trial of its travoprost intraocular implant in a 12-month cohort of glaucoma patients. The company’s iDose device is placed during a micro-invasive procedure and filled with a special formulation of travoprost – a drug used to reduce intraocular pressure. The implant continuously delivers therapeutic levels of travoprost within the eye and when it’s depleted, the iDose is removed and replaced. Get the full story at our sister site, Drug Delivery Business News. The post Glaukos touts Ph2 glaucoma trial for drug-eluting implant appeared first on Mas...
Source: Mass Device - January 10, 2018 Category: Medical Devices Authors: Sarah Faulkner Tags: Clinical Trials Drug-Device Combinations Optical/Ophthalmic Pharmaceuticals Wall Street Beat Glaukos Source Type: news

KTU students are developing dissolving lenses for glaucoma treatment
(Kaunas University of Technology) Students' team from Kaunas University of Technology (KTU) is working on a development of dissolving contact eye lenses, which can be of great assistance for those suffering from glaucoma. According to statistics, glaucoma is the most common cause of preventable, irreversible blindness -- it is responsible for 12.3 percent of blindness worldwide. It is being estimated that by the year 2020 there will be almost 80 million people in the world suffering from the condition. (Source: EurekAlert! - Biology)
Source: EurekAlert! - Biology - January 9, 2018 Category: Biology Source Type: news

Visual Field Testing Feasible in Children With Glaucoma Visual Field Testing Feasible in Children With Glaucoma
Static perimetry is feasible for visual field testing in children with glaucoma as young as age 5 years, and kinetic perimetry provides complementary results in older children, according to findings from the Optimal Perimetric Testing in Children (OPTIC) study.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - January 5, 2018 Category: Consumer Health News Tags: Medscape Today News Source Type: news

UCLA volunteers provide free health care at downtown L.A. mega clinic
With the strongly held belief that access to health care should be available to everyone — not just the insured — nearly 200 volunteers from UCLA joined an effort to provide free services to more than 2,000 people at a three-day Care Harbor community clinic.“Los Angeles is still one of the leading areas of people without insurance or access to care and it’s a problem for the community,” said Dr. Patrick Dowling, professor and chair of the  UCLA Department of Family Medicine, who led the UCLA volunteer contingent at Care Harbor ’s seventh health care mega clinic. “I’...
Source: UCLA Newsroom: Health Sciences - January 4, 2018 Category: Universities & Medical Training Source Type: news

Glaukos seeks FDA IDE nod for iStent infinite trial
Glaukos (NYSE:GKOS) said today it submitted an investigational device exemption application to the FDA as it looks to launch a study of its iStent infinite trabecular micro-bypass system. The San Clemente, Calif.-based company’s iStent infinite is designed to reduce elevated intraocular pressure in patients with refractory glaucoma, and includes three heparin-coated titanium stents and an auto-injection system. The stents are designed to be injected around the Schlemm’s canal to allow the natural physiological outflow of aqueous humor to lower IOP, Glaukos said. Glaukos is looking to launch a prospective, ...
Source: Mass Device - January 3, 2018 Category: Medical Devices Authors: Fink Densford Tags: Clinical Trials Food & Drug Administration (FDA) Optical/Ophthalmic Glaukos Source Type: news

Tea for your eyes: Research finds a daily cup of hot tea reduces the risk of glaucoma by a shocking 74%
(Natural News) Good news for anyone who is a fan of tea — research indicates that a daily cup of tea may reduce the likelihood of glaucoma. According to a study made by researchers from the University of California, people who drink tea at least once a day “are 74 percent less likely” to be diagnosed... (Source: NaturalNews.com)
Source: NaturalNews.com - January 2, 2018 Category: Consumer Health News Source Type: news

Drinking Hot Tea Linked to Lowered Glaucoma Risk Drinking Hot Tea Linked to Lowered Glaucoma Risk
People who drink hot tea daily may be less likely than others to develop glaucoma symptoms, U.S. researchers say.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - January 2, 2018 Category: Consumer Health News Tags: Medscape Today News Source Type: news

Drug makeover: When a drug underperforms, Big Pharma renames it, labels it for another use and jacks up the price
(Natural News) A drug that treats periodic paralysis may be pricing those afflicted with the condition out of the market. Originally a medicine approved for glaucoma treatment, the U.K. National Health Service made Daranide available for the equivalent of about $500 U.S. dollars for a year’s supply. Daranide reportedly didn’t work well for the eye disease,... (Source: NaturalNews.com)
Source: NaturalNews.com - January 2, 2018 Category: Consumer Health News Source Type: news

Drinking hot tea linked to lowered glaucoma risk
(Reuters Health) - People who drink hot tea daily may be less likely than others to develop glaucoma symptoms, U.S. researchers say. (Source: Reuters: Health)
Source: Reuters: Health - January 1, 2018 Category: Consumer Health News Tags: healthNews Source Type: news

This glaucoma specialist has a clear vision of what she wants for metro Orlando
Cutting-edge technology and safety are some of the things Courtney Bovee has her eye on. (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - December 29, 2017 Category: Pharmaceuticals Authors: Anjali Fluker Source Type: news

Angle Recession Glaucoma
(Source: eMedicineHealth.com)
Source: eMedicineHealth.com - December 28, 2017 Category: General Medicine Source Type: news

Glaukos files PMA bid for iStent Inject glaucoma treatment
Glaukos (NYSE:GKOS) said today that it filed for pre-market approval from the FDA of its iStent Inject trabecular micro-bypass stent for treating glaucoma. San Clemente, Calif.-based Glaukos said the device is designed to treat mild-to-moderate open-angle glaucoma in patients undergoing cataract surgery. It used a pair of heparin-coated titanium stents in a pre-loaded auto-injection system that allows them to be injected into multiple trabecular meshwork locations via a single corneal entry point. “This PMA submission marks a significant milestone for Glaukos as we continue to deliver our deep pipeline of n...
Source: Mass Device - December 27, 2017 Category: Medical Devices Authors: Brad Perriello Tags: Food & Drug Administration (FDA) Optical/Ophthalmic Regulatory/Compliance Glaukos Source Type: news

FDA approves Aerie drug sooner than expected – sales staff to grow
For Aerie Pharmaceuticals (Nasdaq: AERI) – a Duke University spinout that is in the process of building out its research and development team locally – Christmas did indeed come early. Aerie announced Dec. 18 that the U.S. Food and Drug Administration has approved its eye drop Rhopressa for the treatment of glaucoma and hypertension i n the eyes, two months ahead of its scheduled PDUFA date. The company also said it has plans to hire a sprawling field sales force. "We are proud of the work we… (Source: bizjournals.com Health Care:Physician Practices headlines)
Source: bizjournals.com Health Care:Physician Practices headlines - December 26, 2017 Category: American Health Authors: Jennifer Henderson Source Type: news

Glaucoma and quality of life: fall and driving risk - Montana CL, Bhorade AM.
PURPOSE OF REVIEW: Numerous population-based studies suggest that glaucoma is an independent risk factor for falling and motor vehicle collisions, particularly for older adults. These adverse events lead to increased healthcare expenditures and decreased q... (Source: SafetyLit)
Source: SafetyLit - December 25, 2017 Category: International Medicine & Public Health Tags: Age: Elder Adults Source Type: news

Traumatic glaucoma due to paintball injuries: a case series - Lee KM, Seery C, Khouri AS.
PURPOSE: To study the management and outcomes of patients with paintball injuries resulting in traumatic glaucoma. METHODS: A retrospective review was performed, identifying four patients with a confirmed diagnosis of traumatic glaucoma secondary t... (Source: SafetyLit)
Source: SafetyLit - December 25, 2017 Category: International Medicine & Public Health Tags: Recreational and Sports Issues Source Type: news

Mixed Data for Fatty Acid Intake and Glaucoma (CME/CE)
(MedPage Today) -- Lower risk with higher EPA, DHA intake but not total PUFA (Source: MedPage Today Primary Care)
Source: MedPage Today Primary Care - December 24, 2017 Category: Primary Care Source Type: news

Can a Cup of Hot Tea a Day Help Preserve Eyesight?
Hot tea, but not iced tea or coffee, was linked to a lower risk of glaucoma. (Source: NYT Health)
Source: NYT Health - December 20, 2017 Category: Consumer Health News Authors: NICHOLAS BAKALAR Tags: Tea Eyes and Eyesight Glaucoma Source Type: news

Aerie Pharmaceuticals Announces U.S. FDA Approval of Rhopressa (netarsudil ophthalmic solution) 0.02% for Patients with Open-Angle Glaucoma or Ocular Hypertension
IRVINE, Calif.--(BUSINESS WIRE)--Dec. 18, 2017-- Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) (Aerie or the Company), an ophthalmic pharmaceutical company focused on the discovery, development, and commercialization of first-in-class therapies for the... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - December 19, 2017 Category: Drugs & Pharmacology Source Type: news

Aerie's Glaucoma Treatment Gets Early FDA Approval Aerie's Glaucoma Treatment Gets Early FDA Approval
Aerie Pharmaceuticals Inc said on Monday the U.S. Food and Drug Administration approved its eyedrop, Rhopressa, as a treatment for glaucoma, two months ahead of the expected date.FDA Approvals (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - December 19, 2017 Category: Consumer Health News Tags: Ophthalmology News Alert Source Type: news

Glaukos wins FDA nod for IDE trial of iStent SA
Glaukos (NYSE:GKOS) said today it won FDA investigational device exemption to launch a pivotal study of its iStent SA trabecular micro-bypass system designed to treat glaucoma. The San Clemente, Calif.-based company’s iStent SA is designed to reduce intraocular pressure in psuedophakic, mild-to-moderate open-angle, pigmentary or psuedoexfoliative glaucoma patients, the company said. The system includes 2 micro-scale titanium stents in an auto-injection system which can be injected into trabecular meshwork locations through a single corneal entry point to restore physiological outflow of aqueous humor into the Sc...
Source: Mass Device - December 19, 2017 Category: Medical Devices Authors: Fink Densford Tags: Clinical Trials Food & Drug Administration (FDA) Optical/Ophthalmic Regulatory/Compliance Glaukos Source Type: news

Aerie ’s glaucoma eye drops win early FDA nod
Aerie Pharmaceuticals (NSDQ:AERI) won an early FDA nod for its glaucoma drug, Rhopressa. The agency was slated to make a decision about the company’s eye drops in February. The win for Aerie came after an expert panel voted 9-1 in the drug’s favor. Studies have found that Rhopressa lowers elevated intraocular pressure in the eye, but analysts have noted that the twice-daily generic timolol ophthalmic solution 0.5% is more effective for patients with severe cases of glaucoma. Get the full story at our sister site, Drug Delivery Business News. The post Aerie’s glaucoma eye drops win early FDA...
Source: Mass Device - December 19, 2017 Category: Medical Devices Authors: Sarah Faulkner Tags: Drug-Device Combinations Food & Drug Administration (FDA) Optical/Ophthalmic Pharmaceuticals Wall Street Beat Aerie Pharmaceuticals Source Type: news

Aerie's glaucoma treatment gets early FDA approval
(Reuters) - Aerie Pharmaceuticals Inc said on Monday the U.S. Food and Drug Administration approved its eyedrop, Rhopressa, as a treatment for glaucoma, two months ahead of the expected date. (Source: Reuters: Health)
Source: Reuters: Health - December 18, 2017 Category: Consumer Health News Tags: healthNews Source Type: news

Bausch andamp; Lomb Begins Distribution Of VYZULTA(TM) (latanoprostene bunod ophthalmic solution), 0.024% To U.S. Wholesalers
LAVAL, Quebec, Dec. 18, 2017 -- (Healthcare Sales & Marketing Network) -- Valeant Pharmaceuticals International, Inc.'s (NYSE: VRX and TSX: VRX) ("Valeant") wholly owned subsidiary, Bausch & Lomb, a leading global eye health company, today ... Biopharmaceuticals, Ophthalmology, Product Launch Valeant Pharmaceuticals, Bausch & Lomb, VYZULTA, latanoprostene, glaucoma (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - December 18, 2017 Category: Pharmaceuticals Source Type: news

Could a Hot Cup of Tea Preserve Your Vision?
Source: HealthDay Related MedlinePlus Pages: Glaucoma (Source: MedlinePlus Health News)
Source: MedlinePlus Health News - December 15, 2017 Category: Consumer Health News Source Type: news

Medical News Today: Could a cup of hot tea each day reduce the risk of glaucoma?
Glaucoma, an eye condition that can lead to blindness, affects a significant number of older adults. Could a household beverage help to shield us from it? (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - December 15, 2017 Category: Consumer Health News Tags: Eye Health / Blindness Source Type: news

How your daily cup of tea could beat glaucoma
People who drink a cup of hot tea at least once a day are 74 per cent less likely to be diagnosed with glaucoma - a severe eye problem which affects 600,000 people in Britain. (Source: the Mail online | Health)
Source: the Mail online | Health - December 15, 2017 Category: Consumer Health News Source Type: news

Could a Hot Cup of Tea Preserve Your Vision?
The study of U.S. adults found that people who drank hot tea on a daily basis were 74 percent less likely to have glaucoma, compared to those who were not tea fans. (Source: WebMD Health)
Source: WebMD Health - December 15, 2017 Category: Consumer Health News Source Type: news

Could drinking tea really be linked to a lower risk of glaucoma?
A study has found a link between hot tea and a lower risk of glaucoma, but experts say there ’s no evidence that a cuppa will protect you from the conditionDrinking hot tea could be linked to a lower risk of having an eye condition that can lead to blindness, research has suggested – although experts say the study does not show that the brew offers any protective effect.Glaucoma is an eye condition in which the pressure of fluids inside the eye damages the optic nerve – and can lead to blindness if left undetected. Many are unaware they have the condition, and while the risk of glaucoma increases with age...
Source: Guardian Unlimited Science - December 14, 2017 Category: Science Authors: Nicola Davis Tags: Medical research Tea Health Science Society Source Type: news

Could a Hot Cup of Tea Preserve Your Vision?
THURSDAY, Dec. 14, 2017 -- A spot of hot tea in the afternoon might help you save your sight, new research suggests. The study of U.S. adults found that people who drank hot tea on a daily basis were 74 percent less likely to have glaucoma, compared... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - December 14, 2017 Category: General Medicine Source Type: news

Fear of falling and postural reactivity in patients with glaucoma - Daga FB, Diniz-Filho A, Boer ER, Gracitelli CPB, Abe RY, Medeiros FA.
PURPOSE: To investigate the relationship between postural metrics obtained by dynamic visual stimulation in a virtual reality environment and the presence of fear of falling in glaucoma patients. METHODS: This cross-sectional study included 35 glau... (Source: SafetyLit)
Source: SafetyLit - December 8, 2017 Category: International Medicine & Public Health Tags: Age: Elder Adults Source Type: news

Most glaucoma patients don't ask about medication costs
(Wolters Kluwer Health) Less than one-third of patients with glaucoma talk to their doctor about the costs of medications needed to control their disease, reports a study in the December issue of Optometry and Vision Science, the official journal of the American Academy of Optometry. The journal is published by Wolters Kluwer. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - December 1, 2017 Category: International Medicine & Public Health Source Type: news

Factors associated with the occurrence of a fall in subjects with primary open-angle glaucoma - Adachi S, Yuki K, Awano-Tanabe S, Ono T, Murata H, Asaoka R, Tsubota K.
BACKGROUND: The aim of the study is to investigate risk factors for future falls in subject with primary open angle glaucoma (POAG). METHODS: All participants answered the following question at their baseline ophthalmic examination: Have you had an... (Source: SafetyLit)
Source: SafetyLit - November 30, 2017 Category: International Medicine & Public Health Tags: Age: Elder Adults Source Type: news